CRISPR Therapeutics Reports Q4 Loss, Stock Price Target Raised

CRISPR Therapeutics (CRSP) has seen its stock price targets adjusted by several analysts following its recent earnings report, which exceeded expectations with a narrower-than-anticipated loss of $0.44 per share. Truist Financial raised its price target from $100 to $120, while Bank of America slightly increased its target to $86. Despite a decline in revenue and a net loss of $37.3 million for Q4 2024, the company maintains a strong cash position of approximately $1.9 billion and anticipates significant clinical advancements in the upcoming year. The global launch of its CASGEVY therapy and ongoing trials for next-generation CAR T therapies are key highlights of its operational progress. Overall, analysts remain optimistic about CRISPR Therapeutics, with a consensus price target suggesting a potential upside of 56% over the next 12 months. The company's pioneering role in gene editing continues to position it favorably within the biotech sector.